Romosozumab and cardiovascular safety in Japan
10.1016/j.afos.2021.09.002
- Author:
Yasuhiro TAKEUCHI
1
Author Information
1. Toranomon Hospital Endocrine Center, Tokyo, Japan
- Publication Type:Review article
- From:Osteoporosis and Sarcopenia
2021;7(3):89-91
- CountryRepublic of Korea
- Language:English
-
Abstract:
Romosozumab is a potent pharmacological tool to prevent fractures in osteoporosis patients, and its mechanism of action is distinct from any other drugs. The efficacy of romosozumab to prevent osteoporotic fractures is remarkable. However, there remains a concern of increased cardiovascular adverse events. Further relevant investigations are essential to understand whether romosozumab is actually involved in the development of cardiovascular events or not. We need more robust evidence to establish an appropriate and reasonable guide to prescribe romosozumab in our clinical practice.
